U.S. markets open in 2 hours 4 minutes
  • S&P Futures

    3,825.50
    -8.50 (-0.22%)
     
  • Dow Futures

    30,883.00
    -53.00 (-0.17%)
     
  • Nasdaq Futures

    11,772.00
    -36.50 (-0.31%)
     
  • Russell 2000 Futures

    1,736.60
    -5.10 (-0.29%)
     
  • Crude Oil

    100.17
    +0.67 (+0.67%)
     
  • Gold

    1,761.00
    -2.90 (-0.16%)
     
  • Silver

    19.14
    +0.01 (+0.07%)
     
  • EUR/USD

    1.0202
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.86
    +0.33 (+1.20%)
     
  • GBP/USD

    1.1908
    -0.0044 (-0.37%)
     
  • USD/JPY

    135.4500
    -0.3920 (-0.29%)
     
  • BTC-USD

    20,066.79
    +287.31 (+1.45%)
     
  • CMC Crypto 200

    434.82
    -5.20 (-1.18%)
     
  • FTSE 100

    7,150.90
    +125.43 (+1.79%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance.

  • Wells Fargo lowered the price target to $265 from 321, which is equivalent to a 52.2% upside.

  • At 9.5x (down from 12x as peer group valuation has been compressed) with a 2023 sales estimate of $1.02 billion, PEN shares would trade essentially in line with its peers, analysts write.

  • Q1 revenue of $203.9 million (+21.8% ex-FX) beat the consensus of $195.04 million and Wells Fargo's estimate of $195.2 million, including $5 million from an earlier-than-expected start of vascular thrombectomy sales in China, notes Wells Fargo.

  • For 2022, the company maintained its revenue guidance of $860 million -$875 million.

  • With multiple new Neuro and Vascular launches expected over the next 18 months, PEN expects its revenue growth to accelerate in 2023, which puts the company well on track to exceed $1 billion in total revenue next year.

  • The analysts believe PEN's incremental pipeline disclosure on the call reflects management's confidence in the upcoming launches and the business's growth potential, despite incremental macro headwinds and ongoing competitive pressure.

  • Price Action: PEN shares are down 1.50% at $171.47 during the market session on the last check Wednesday.

Latest Ratings for PEN

Mar 2022

Needham

Initiates Coverage On

Hold

Feb 2022

Citigroup

Maintains

Buy

Feb 2022

JP Morgan

Maintains

Overweight

View More Analyst Ratings for PEN

View more earnings on PEN

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.